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Background: Asthma is one of the most common non-communicable respiratory diseases, affecting about 6% of
general population. Severe asthma, even if afﬂicts a minority of asthmatics, drives the majority of costs of the
disease. The aim of this study is to create a pharmacoeconomic model to predict the costs of corticosteroid-related
adverse events in severe asthmatics and applying it to the ﬁrst published epidemiologic data from the Severe
Asthma Network in Italy (SANI) registry.
Methods: The analysis was conducted from the perspective of the Italian National Healthcare System (INHS).
Model inputs, derived from literature, included: asthma epidemiology data, frequency of adverse events, per-
centage of severe asthma treated with OCS and adverse event cost (Diagnosis-Related Group (DRG) national
tariffs). We estimated costs per different patient groups: non-asthma controls, mild/moderate and severe asth-
matics. Final results report estimated direct cost per patient and total direct cost for overall target population,
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G.W. Canonica et al. WAO Journal 12 (2019) 29–35Results: Based on epidemiological data input, in Italy, asthmatic subjects resulted about 3,999,600, of which
199,980 with severe asthma. The number of patients with severe asthma OCS-treated was estimated at 123,988.
Compared to the non-asthma control cohort and to that with moderate asthma annual cost per severe asthmatic
patient resulted respectively about €892 and €606 higher, showing a corticosteroids shadow cost ranging from
45% to 30%.
Applying the cost per patient to the target population identiﬁed for Italy, the budget impact model estimated a
total annual cost related to OCS-related adverse events of €242.7 million for severe asthmatics. In respect with
non-asthmatic and moderate population, an incremental expenditure of about € 110.6 million and €75.2,
respectively, were shown.
Conclusions: Our study provides the ﬁrst estimates of additional healthcare costs related to corticosteroid induced
adverse events in severe asthma patient. Budget impact model results highlighted the relevant economic impact of
OCS-related adverse events in severe asthma patients. The future extrapolation of additional data from SANI
registry will support the development of a model to investigate the role of corticosteroids sparing drugs.1. Introduction
Asthma is one of the most common non-communicable respiratory
disease, affecting about 6% of general population, that is currently more
than 300 millions of people in the world1,2; the trend of asthma preva-
lence seems to be at least stable,1 if not even increasing in the last few
years.2,3 This epidemiological situation accounts for high and increasing
health-related costs (direct and indirect),4–9 particularly in those patients
with suboptimal control of asthma.10,11
Most of the patients with asthma achieve a good control of the disease
using regularly low-to-medium doses of inhaled corticosteroidsother
controllers, but a small proportion (accounting about 3.5–10% of all
asthmatics12–15) requires high dose of these drugs (and/or systemic
corticosteroids) to be controlled or remains uncontrolled despite this
therapy: these patients are deﬁned as “severe asthmatics” according to
the latest European Respiratory Society (ERS)/American Thoracic Soci-
ety (ATS) guidelines.16 Severe asthma, although afﬂicting a minority of
these patients, drives most costs of the disease.17
Moreover, it is precisely the patients with more severe asthma
(particularly if they have associated comorbidities and high peripheral
eosinophils levels) who use systemic corticosteroids more frequently and
at high dosages, with an increased risk of corticosteroid-related adverse
events.18–20 Indeed, it is known that systemic corticosteroids are not
without side effects, and that these are more frequent and severe in pa-
tients who use them continuously or frequently.21,22 The major adverse
events related to the use of systemic corticosteroids (that are common to
patients using high doses of inhaled corticosteroids for prolonged time23)
are: hypertension, osteoporosis and bone fracture, cataract and glau-
coma, diabetes, respiratory infections, reduced growth velocity in chil-
dren, and hypothalamic-pituitary-adrenal axis suppression.
Few studies analysed the impact, in terms of costs, of corticosteroid-
related adverse events in several diseases, including asthma19,20,22,24–27:
the estimated annual cost in asthmatics ranges from about 600 Euros26 to
about 5000 Euros in more severe patients.27
The aim of this study is to create a pharmacoeconomic model to
predict the costs of corticosteroid-related adverse events in severe asth-
matics and applying it to the ﬁrst published epidemiologic data from the
Severe Asthma Network in Italy (SANI) registry.28,29
2. Materials and methods
2.1. Study design
A budget impact model (BIM) was developed to evaluate the phar-
macoeconomic consequences of oral corticosteroid adverse events (OCS-
AE) in adult patients with severe asthma. The analysis was conducted
through a dynamic simulation model in Microsoft Excel® and carried out
from the perspective of the Italian National Healthcare System (INHS).
Our study initially provided a literature review aimed to identify data on:30 asthma epidemiology
 asthmatic comorbidities related to corticosteroids use
 frequency of adverse events in severe asthma patients
 adverse events cost
Model inputs included asthma epidemiology data, frequency of
adverse events, percentage of severe asthma patients treated with OCS
and adverse events cost. After identifying the study population and main
OCS-related adverse events in adult's asthma patients, the economic
impact of adverse events was estimated based on adverse events rate and
events cost. Economic evaluation was conducted considering a main
scenario, including all adverse events considered in a Sweeney's et al
study that investigated the prevalence of systemic corticosteroid-induced
morbidity in severe asthma using data from Optimum Patient Care
Research Database (OPCRD) and British Thoracic Society (BTS) Difﬁcult
Asthma Registry.19 Speciﬁcally, we adopted prevalence data obtained
from OPCRD database that included 7195 subjects in three age and
gender matched groups: severe asthma (808), mild/moderate asthma
(3975) and non-asthma controls (2412): patients with SA requiring
regular OCS (GINA step 5) were compared with patients with mild/-
moderate asthma and non-asthmatic controls.
Adverse events evaluation was developed adopting Diagnosis-
Related Group (DRG)-based national tariffs (diagnosis-related group
tariffs system). In addition, an analysis subgroup, including some of
most common OCS-related adverse events reported in available studies
was considered: we researched cost of illness studies available in
literature for Italy for diseases in analysis in order to use an alternative
evaluation method, not related only to the acute event as it happens
with the DRG system, and to observe their impact on the total. Based on
different prevalence rates of morbidities associated with systemic ste-
roid exposure provided by literature,19 we estimated costs per different
patient groups: non-asthma controls, mild/moderate and severe asth-
matics. Combining epidemiology data with frequency and OCS-related
adverse events cost, we obtained budget impact analysis results. Final
results report estimated direct cost per patient and total direct cost for
overall target population, showing economic impact related to corti-
costeroid complications, potentially avoidable if these drugs were no
longer administered.
Lastly, in order to assess the robustness of results, a deterministic
sensibility analysis was developed changing main parameters used for
the calculation (cost of adverse events and prevalence rates of OCS-
related adverse events) by 20%. In addition, for event costs we
considered DRG costs related to Lombardy Region, as an alternative to
national tariffs given the variability on the territory.2.2. Study population
In order to obtain the target population, we started from national
epidemiological data derived from Italian National Statistical Institute
Table 3
Asthma comorbidities: cost per event.
Comorbidity Event cost
Type II diabetes €1391.49
Obesity (BMI >30) €1757.84
Osteopenia €940.33
Osteoporosis €1037.82
Fracture €1984.96
Dyspeptic disorders €958.51
Glaucoma €1051.07
Cataract €1051.07
Cardiovascular disease €2096.82
Hypertension €963.36
Psychiatric disorders €1941.81
Hypercholesterolaemia €428.43
Sleep disorder €1408.88
Chronic kidney disease €3734.46
Table 4
Asthma comorbidities: cost of illness study results.
Comorbidity Cost of Illness (mean annual cost)
Type II diabetes € 2792
Obesity € 1166
Osteoporosis € 1325
Glaucoma € 734
Chronic kidney disease € 4508
Pagano et al. Nutrition, Metabolism & Cardiovascular Diseases (2016).
Colao A et al. BMJ Open 2017;7:e013899.
Degli Esposti L, et al. Farmeconomia e percorsi terapeutici 2011; 12(3).
Koleva D et al. Ophthalmologica 2007; 221: 340-347.
Turchetti G et al.Eur J Health Econ (2017) 18:847–858.
Table 1
Study population: demographic data input.
Demographic data
Italian resident population (2017) 60,589,445
Asthma prevalence in Italy 6.60%
SA patients of total asthmatics 5%
SA patients treated with OCS 62%
G.W. Canonica et al. WAO Journal 12 (2019) 29–35(ISTAT).30 As shown in Table 1, a 6.6% of asthma prevalence was applied
to the total resident population in Italy, and 5% of asthmatics were
considered to be affected by severe asthma (based on literature and
expert opinion).3,28
Finally, it was considered that 62% of patients with severe asthma
were chronically treated with OCS, as emerged from the ﬁrst extractions
from SANI database (Severe Asthma Network in Italy).29
2.3. Adverse events rate
Rates of OCS-related adverse events were provided from an obser-
vational study published by Sweeney et al., Table 2. The study was based
on Optimum Patient Care Research Database (UK setting) and compared
patients with SA requiring regular OCS with patients with mild/mod-
erate asthma and non-asthmatic controls (rhinitis diagnosis with no
asthma diagnosis/asthma drugs and no exposure to OCS). The aim of
Sweeney's study was to determine the prevalence of systemic
corticosteroid-induced morbidity in severe asthma over 2-year analysis.
Subjects (7195) had at least 2 years of continuous medical records and
were aged >12 years.
2.4. Adverse events cost
Economic evaluation of OCS-related adverse events was conducted by
DRG Tariffs System, Table 3. This system classiﬁes all patients in ho-
mogeneous groups according to resources absorption, allowing to
economically quantify the use of resources and to provide an estimate of
the cost per acute event from the INHS perspective.
Moreover, in order to extrapolate data cost from literature, we
adopted results from cost of illness studies available for Italy to imple-
ment model subgroup analysis. We considered cost of the following
illness: type 2 diabetes mellitus (T2DM), obesity, osteoporosis, glaucoma
and chronic kidney disease, Table 4.31–35Table 2
Prevalence rates of potential systemic corticosteroid-induced comorbidity.
Comorbidity Prevalence ratesa
Non-astma
controls
Mild/moderate
Asthma
Severe
Asthma
% % %
Type II diabetes 6% 7% 10%
Obesity (BMI >30) 23% 35% 42%
Osteopenia 2% 2% 10%
Osteoporosis 3% 4% 16%
Fracture 4% 3% 5%
Dyspeptic disorders 24% 34% 65%
Glaucoma 3% 3% 4%
Cataract 4% 5% 9%
Cardiovascular disease 7% 7% 10%
Hypertension 25% 29% 34%
Psychiatric disorders 25% 31% 38%
Hypercholesterolaemia 11% 14% 15%
Sleep disorder 2% 3% 4%
Chronic kidney disease 7% 9% 14%
Sweeney J et al. Thorax 2016; 71:339–346.
a 2-year study period.
313. Results
Based on epidemiological data input, in Italy, asthmatic subjects
turned out to be about 3,999,600, of whom 199,980 with severe asthma.
The number of patients with severe asthma OCS-treated was estimated to
be 123,988 which represents the proportion of subjects potentially at risk
of developing morbidities associated with systemic steroid exposure.
The cost of OCS-related adverse events in the main scenario was
derived by combining the cost of each event with the relative rate.
Annual costs per patient related to OCS-related adverse events in non-
asthma control, mild/moderate, and severe asthma groups resulted
equal to €1065,27, €1350,96 and €1957,50 respectively, Table 4.
Compared to the non-asthma control cohort, the annual per patient
cost related to OCS-related adverse events resulted about €892 and €285
higher in severe asthma and moderate/mild cohort respectively. Annual
per patient cost difference between asthmatic groups was about €606
(see Table 5).
We extended the total annual cost for patient to the estimated severe
asthma Italian population in treatment with OCS (n ¼ 123,988) in order
to obtain budget impact results: (Fig. 1).
Comparing severe asthma annual costs with those of non-asthmatic
population, an incremental expenditure of about € 110.6 million was
shown, which was reduced to about € 75.2 compared to the moderate
asthma. The difference between the population with moderate asthma
compared to the non-asthmatic control was lower, reaching approxi-
mately €35.4 million (Fig. 2).
3.1. Subgroup analysis
We evaluated the economic impact of the ﬁve most common OCS-
adverse event, considering cost of illness studies available, in order to
adopt an alternative method to DRG tariffs. The results are shown in
Fig. 3. Speciﬁcally, the subgroup analysis allowed to highlight the eco-
nomic impact exercised by type 2 diabetes, obesity, fractures, glaucoma
Fig. 1. Annual cost related to oral corticosteroids-related adverse events in
target population.
Fig. 2. Incremental cost scenario: cost related to oral corticosteroids-related
adverse events in main analysis.
Fig. 3. Incremental cost scenario: cost related to oral corticosteroids-related
adverse events in sub-analysis scenario.
Table 5
Cost per patient related to comorbidities.
Comorbidity Non-asthma
control
Moderate
asthma
Severe
asthma
Type II diabetes € 83,49 € 97,40 € 139,15
Obesity (BMI >30) € 404,30 € 615,24 € 738,29
Osteopenia € 18,81 € 18,81 € 94,03
Osteoporosis € 31,13 € 41,51 € 166,05
Fracture € 79,40 € 59,55 € 99,25
Dyspeptic disorders € 230,04 € 325,89 € 623,03
Glaucoma € 31,53 € 31,53 € 42,04
Cataract € 42,04 € 52,55 € 94,60
Cardiovascular disease € 146,78 € 146,78 € 209,68
Hypertension € 240,84 € 279,38 € 327,54
Psychiatric disorders € 485,45 € 601,96 € 737,89
Hypercholesterolaemia € 47,13 € 59,98 € 64,26
Sleep disorder € 28,18 € 35,22 € 56,36
Chronic kidney disease € 261,41 € 336,10 € 522,83
Total for 2-year analysis € 2130.54 € 2701.91 € 3915.00
Annual total cost 1065.27 € 1350.96 € 1957.50 €
Table 6
Sensibility analysis results.
Main scenario Annual cost Incremental cost
Non-asthma control € 2131 Severe asthma
vs control
€ 1784
Moderate asthma € 2702 Severe asthma
vs moderate
€ 1213
Severe asthma € 3915 Moderate asthma
vs control
€ 571
Lombardia DRG cost Annual cost Incremental cost
Non-asthma control € 2441 Severe asthma
vs control
€ 2263
Moderate asthma € 3099 Severe asthma
vs moderate
€ 1605
Severe asthma € 4704 Moderate asthma
vs control
€ 658
DRG National tarriffs -20% Annual cost Incremental cost
Non-asthma control € 1704 Severe asthma
vs control
€ 1428
Moderate asthma € 2162 Severe asthma
vs moderate
€ 970
Severe asthma € 3132 Moderate asthma
vs control
€ 457
DRG National tarriffs þ20% Annual cost Incremental cost
Non-asthma control € 2557 Severe asthma
vs control
€ 2141
Moderate asthma € 3242 Severe asthma
vs moderate
€ 1456
Severe asthma € 4698 Moderate asthma
vs control
€ 686
Prevalence rates -20% Annual cost Incremental cost
Non-asthma control € 1704 Severe asthma
vs control
€ 1428
Moderate asthma € 2162 Severe asthma
vs moderate
€ 970
Severe asthma € 3132 Moderate asthma
vs control
€ 457
Prevalence rates þ20% Annual cost Incremental cost
Non-asthma control € 2557 Severe asthma
vs control
€ 2141
Moderate asthma € 3242 Severe asthma
vs moderate
€ 1456
Severe asthma € 4698 Moderate asthma
vs control
€ 686
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G.W. Canonica et al. WAO Journal 12 (2019) 29–35and chronic kidney disease according to literature data. These ﬁve dis-
eases alone were able to result in a total annual cost equal to €92.7
million in the population with severe asthma, involving an additional
expenditure of approximately €41.5 million compared to control and
€26.3 million compared to populations with moderate asthma (Fig. 3).3.2. Sensibility analysis
In Table 6 sensibility analysis results are shown.
Using a deterministic sensitivity analysis (DSA), we investigated the
sensitivity of the results from the model-based analysis to variations in
cost of adverse events and prevalence rates of OCS-related adverse
events, which are among the main input parameters used for the cost
analysis. Speciﬁcally, varying these values by 20%, no signiﬁcant
changes in the ﬁnal results were reported, highlighting the robustness of
the budget impact analysis result.
4. Discussion
This budget impact analysis highlighted the signiﬁcant economic
burden of morbidity related to systemic corticosteroid exposure in severe
asthma population from the Italian NHS perspective. Our analysis,
starting from national demographic data, asthma epidemiological data
and adopting ﬁrst published extractions from the Severe Asthma
Network in Italy (SANI) registry, identiﬁed the proportion of subjects
potentially at risk of developing comorbidities associated with systemic
steroid exposure and showed that co-morbid costs were greater in the
severe asthma patients, subjected to treatment with high-medium oral
corticosteroids, compared to moderate and non-asthmatic cohort.
Total annual cost per patient associated with comorbid conditions
due to OCS use was estimated at €1957.50 for the severe asthma cohort,
almost twice that non-asthmatic population, and more than 30%
compared to the population with moderate asthma, (€1350.96). Annual
cost per patient difference between severe and moderate groups was
about €606. The cost was determined by the higher prevalence of OCS-
related adverse events in severe asthma cohort, considering the corre-
lation between regular intensive use of systemic steroid therapy and
disease onset and consequent impact on cost. For the analysis we
considered the co-morbidities most frequently associated with the use of
corticosteroids taken from the Sweeney's study,19 which provided events
prevalence data for the three cohorts in analysis.
Applying the cost per patient to the target population identiﬁed for
Italy, the budget impact model estimated a total annual cost related to
OCS-related adverse events of €242.7 million for severe asthmatics. In
respect with non-asthmatic and moderate asthma population, an incre-
mental expenditure of about € 110.6 million and €75.2, respectively, was
shown. The micro-costing analysis conducted based on cost of illness
studies available for Italy, allowed to evaluate the impact of a subset of
diseases, offering an alternative economic evaluation method. Five OCS-
related adverse events alone, type 2 diabetes, obesity, fractures, glau-
coma and chronic kidney disease, resulted in a total annual cost equal to
€92.7 million in the population with severe asthma. The robustness of
main analysis was conﬁrmed by sensitivity analysis. Moreover, given
regional tariffs variability in Italy for acute care hospital services, in order
to provide an example of regional valorisation, we adopted DRG tariffs
used in Lombardy region, recognized higher than the national average.
According to international guidelines, oral corticosteroid (OCS)
treatment in asthma should be reserved to acute exacerbations (with
short course of therapy) or to those severe patients remaining clinically
uncontrolled or at high risk for future loss of control, despite high dose of
inhaled corticosteroids (ICS) plus another controller, such as long-term
beta2-agonists (better if combined, in a single inhaler, with ICS),
leukotriene-receptor antagonists (LTRA), tiotropium or theophylline.36
Anyway, even in case of severe asthma, the suggestion is to use low-dose
of OCS as a second-choice treatment after having considered the33possibility to use biologic agents such as anti-IgE or anti-IL5 monoclonal
antibodies.36
However, the ﬁrst published real-life data raised by the SANI reg-
istry29 put in evidence a dramatic situation in which more than 60% of
severe asthmatics are chronically taking OCS, being therefore at high
risk of OCS-related adverse events. An even more dramatic picture
emerged from the updated SANI registry data recently published and
showing a prevalence of OCS users higher than 64% of all severe
asthmatics.37 A similar picture has been described by Zeiger et al. in a
recent retrospective observational cohort study of adults with persistent
asthma: they found an overall prevalence of OCS-treated patients of
about 8.2% which corresponded to the great majority of those with
severe asthma stigmata.18
Putting these real-life data together with the evidence that severe
asthmatics are often affected by comorbidities requiring chronic use of
topical (i.e.: intranasal) or systemic corticosteroids,19 it is easily pre-
dictable that these patients have a high probability to develop cortico-
steroid adverse events. This risk is further increased considering that also
chronic use of high (often higher than suggested) dose of ICS has been
associated with signiﬁcant adverse events.23,38
The high prevalence of OCS use and the well-known impact of these
drugs on the onset of complications, fromminor events to potentially life-
threating conditions, in any case impacting patient's quality of life, have
led to develop studies aimed at considering even their economic impact.
Behind the low acquisition cost of these drugs, the cost associated with
OCS-induced morbidity hides, representing a shadow cost not to be
missed. The signiﬁcance of this topic, also considering current OCS-
sparing effect therapies availability, is demonstrated by various pub-
lished studies that, in line with ours, paid attention to the economic
burden of adverse events associated with drugs exposure.
Some reviews analysed the corticosteroids effect in term of adverse
events and cost considering the effects on more pathologies or focusing
on the asthma only.25,39 Findings from these studies showed systemic
corticosteroids are a common cause of comorbidities and the costs of
managing these events can be substantial. Therefore, clinical and eco-
nomic burden of systemic related adverse events highlights the need for
OCS sparing therapies to be adopted.
Focusing on asthma, some studies have been carried out to evaluate
the risk of systemic corticosteroids complications by steroid exposure and
quantify the associated health care costs and resource use in patients with
severe asthma requiring a regular therapy.
Lefebvre et al. performed a longitudinal, open-cohort, observational
study using health insurance claims data; the adjusted risk of systemic
corticosteroids related complications for patients with medium and high
exposure compared with patients with low exposure and quantify the
resulting health care resource use and costs were estimated: patients with
medium and high systemic corticosteroids exposure had signiﬁcantly
higher risks of steroids related complications versus those with low
exposure.40
Luskin et al with their cross-sectional, matched-cohort, retrospective
study, using a commercial claims database, estimated the prevalence of
possible oral corticosteroid (OCS)-related side effects and health care
resource use and costs in patients with asthma.41 Adults with asthma
diagnosis codes and evidence of asthma medication use were studied.
Patients with high OCS use (30 days of OCS annually) with possible
OCS-related adverse events were more likely to have ofﬁce visits and
hospitalizations than those without possible side effects. High OCS users
with possible side effects had higher adjusted total annual mean health
care costs ($25,168) than those without such side effects ($21,882).41
Our study is consistent with the data reported in literature, high-
lighting the correlation between the severity of asthmatic disease, and
the increase in costs related to systemic corticosteroid-induced morbid-
ities: differences in costs were signiﬁcant between patients with asthma
differentiated by steroid exposure. Moreover, this article is the ﬁrst data
from Italian Registry of Severe Asthma (SANI) that shows economic
impact of OCS-overuse. This result is in line with that emerged from
G.W. Canonica et al. WAO Journal 12 (2019) 29–35Barry's et al study,27 that have prevalence rates of corticosteroid-induced
morbidity in common with our, corresponding to the economic evalua-
tion of the results from the Sweeney study.19 According to UK NHS,
Barry's study aimed to estimate the additional healthcare costs associated
with steroid induced morbidity by comparing three patients' groups:
those with severe asthma, moderate asthma and no asthma. Average
healthcare costs per person per year range from £2603 - £4533 for the
severe asthma cohort, to £978 - £2072 for the mild/moderate asthma
cohort, to £560 - £1324 for the non-asthma control cohort, depending on
different costing scenario considered.27
The excess risk of complications associated with long-term mainte-
nance OCS use and related cost was also estimated by Tilden et al for the
Australian population;26 this study, in addiction, considered
quality-adjusted life year (QALY) losses due to corticosteroids exposure,
focusing on eight disease outcomes signiﬁcantly impacting costs QALY
burden: type II diabetes, myocardial infarction, glaucoma, cataract, ulcer,
osteoporosis, infection, and stroke. Expected annual cost of maintenance
OCS-related disease outcomes resulted $598.32 per patient per year.
Each patient treated with maintenance OCS also reported a QALY loss of
0.0367 per year of treatment. These effects are considered reversible
once patients stop taking maintenance OCS.26
Different strategies have been developed to reduce the use of the
corticosteroid load in asthma,42 ranging from allergy immunotherapy
(not suitable for uncontrolled asthmatics),43 to biologic agents used in
severe patients, as omalizumab,44 mepolizumab,45 benralizumab46 and
dupilumab.47 The biologic treatment of severe asthma, into the context
of a more personalized approach to the patients,48 seems to be a safe
and effective steroid-sparing therapy; biologic agents are generally
quite expensive and this, with payer policies, is currently one of the
main limitation of their use in clinical practice, even if real-life studies
demonstrated that their correct use is globally cost-effectiveness.49–51
To this purpose, the big data coming from registries like SANI will
provide the opportunity to monitor OCS sparing effect of biologic
agents in a real-life setting. However, even considering the more
long-lived biologic agent for severe asthma (omalizumab), there is the
real-life evidence that still a large group of individuals who may beneﬁt
from this drug are not receiving it.52 In the very selected population of
patients followed by tertiary reference centers for severe asthma in
Italy, composed in 95% of cases of patients classiﬁed as GINA V step
severity, the underuse of biologic agents is conﬁrmed: only about 60%
of those eligible to at least one biologic agent are receiving this kind of
therapy.29
Further studies are needed to investigate if a wider use biologic agent
in severe asthmatics may be cost-effective also in terms of reduction of
OCS-related adverse events costs.
Our study provides estimates of additional healthcare costs related
to corticosteroid induced adverse events in severe asthma patients
from the Italian NHS perspective, not analysed previously. Budget
impact model results highlighted the relevant economic impact of
OCS-related adverse events in severe asthma patients, subjected to
regular exposure to corticosteroids, compared to not exposed. The
availability of the ﬁrst epidemiologic data from SANI registry allowed
the deﬁnition of target population based on national real word data.
The future extrapolation of additional data from SANI registry will
support the development of a model populated with national data,
providing an important tool for further analyses and greater robust-
ness. Indeed, use of adverse events prevalence rates derived from a UK
respiratory database (OPCRD)19 could be seen as a limit of our study.
However, it was necessary, because there were no data available for
Italy. To overcome the uncertainty of this data, together with that
associated with the cost of adverse events, we conducted a sensitivity
analysis. Economic evaluation was carried out adopting direct cost
associated with corticosteroids related adverse events management,
according to Italian NHS. Indirect costs were not considered despite
their impact could be relevant due to effects of OCS-related adverse
events on productivity and quality of life loss. Overall, the analysis34conducted can be considered conservative, indeed the number of
evaluable adverse events can be expanded and for economic evalua-
tion we considered unique national tariffs, to achieve greater homo-
geneity, in a context of national variability.
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